The Medicare Bridge demonstration (July 1, 2026–Dec. 2027) lets eligible beneficiaries access select GLP‑1 weight‑loss drugs for a flat $50 monthly co‑pay while CMS pays a negotiated net amount to manufacturers. Strict eligibility rules exclude people with type 2 diabetes, moderate‑to‑severe sleep apnea and MASH, and the program runs outside normal Part D claims processes — with prior authorization routed to a CMS central processor. Operational complexity, limited plan participation in a related BALANCE pilot and large potential federal costs (the CBO estimates up to $30B/year at full uptake) leave the initiative’s long‑term fate uncertain.
Medicare’s GLP‑1 ‘Bridge’ Expands Access — $50 Copay, Tight Rules and Big Cost Questions
WASHINGTON, DC - NOVEMBER 6, 2025: U.S. President Donald Trump, joined by members of the pharmaceutical industry and administration officials, delivers remarks on lowering drug prices. Trump announced that his administration has reached agreements with drugmakers Eli Lilly and Novo Nordisk that would lower the price of some GLP-1 weight loss medications. Consumers can access such drugs on online platforms such as TrumpRx. And, as of July 2026, Medicare beneficiaries can gain access to certain GLP-1 weight loss agents through a Bridge program for $50 a month.(Photo by Andrew Harnik/Getty Images)Getty Images
Beginning July 1, 2026, Medicare launched a temporary Bridge demonstration to provide select glucagon‑like peptide‑1 (GLP‑1) weight‑loss medications to beneficiaries. The initiative aims to broaden access for older adults and some people with disabilities, but clinicians and patients say the program’s eligibility restrictions, administrative steps and fiscal uncertainty make it complicated in practice.
What the Bridge Demonstration Does
The Bridge demonstration runs from July 2026 through December 2027. It allows people age 65 and older and certain disabled beneficiaries to obtain specific GLP‑1 agents — including Zepbound (tirzepatide), Foundayo (orforglipron) and Wegovy (semaglutide) — through a flat $50 monthly co‑payment. CMS has set a negotiated net payment to manufacturers at $245 per prescription per month; the beneficiary co‑payment is collected separately under the Bridge arrangement.
Drug Formulation Rules
Coverage rules differ by product. According to Pharmacy Times, semaglutide is reimbursed in both injectable and tablet forms; tirzepatide is covered only in the KwikPen delivery format (single‑dose vials and other pens are excluded); and orforglipron is reimbursed across dosage strengths. These formulation restrictions affect which dispensers and pharmacies can fulfill prescriptions under Bridge.
Who Is Eligible — And Who Is Not
CMS set strict eligibility criteria. Patients with type 2 diabetes, moderate‑to‑severe sleep apnea, or metabolic dysfunction‑associated steatohepatitis (MASH) are excluded on the rationale that those conditions may already be treated under Medicare’s standard outpatient drug benefit. Body mass index (BMI) rules apply: a BMI of 35 or higher qualifies, or a BMI between 27 and 35 when paired with an obesity‑related comorbidity.
Practical consequence: A beneficiary with BMI 35 who develops moderate sleep apnea can be disqualified and shifted back to their Part D plan — which may not cover the drug or may charge much higher out‑of‑pocket costs.
How It Works Operationally
Although Bridge requires beneficiaries to be enrolled in Part D to qualify, the program operates outside Part D’s normal claims and payment systems. Prescribers must submit prescriptions and prior authorizations directly to a CMS‑managed central processor rather than to the patient’s Part D plan. Claims routed through standard Part D channels are likely to be rejected, and prior‑authorization processing can take several days.
Costs And Fiscal Questions
The Bridge co‑payment is a uniform $50 per month for all participants and does not vary by income; beneficiaries who receive low‑income subsidies under Part D receive no special relief under Bridge. Importantly, Bridge co‑payments do not count toward a beneficiary’s Part D deductible or out‑of‑pocket maximums.
Cost is a central uncertainty. The Congressional Budget Office (CBO) has estimated that if every eligible beneficiary enrolled, annual taxpayer spending could exceed $30 billion; a lower‑uptake scenario (about 20% of eligible beneficiaries) would still cost roughly $6 billion per year. CMS has not publicly released its own detailed cost projections for Bridge or for the related BALANCE pilot.
BALANCE Pilot And Plan Participation
To work within statutory limits that have long barred Medicare from covering drugs solely for weight loss, the administration also designed a five‑year pilot called BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth). BALANCE would have combined manufacturer discounts with voluntary lifestyle support and Part D participation, but plan sponsors did not meet an 80% participation threshold and the pilot was put on indefinite pause. CMS proceeded with the Bridge demonstration as a separate, executive‑led effort.
What’s At Stake
The Bridge demonstration represents a novel federal attempt to expand access to GLP‑1 therapies for obesity. However, restrictive eligibility rules, the program’s operation outside the familiar Part D system, potential gaps in continuity of care when the demonstration ends in December 2027, and unresolved fiscal implications raise questions about the program’s practicality and durability. If Bridge is not extended, many people could face treatment interruptions, weight regain and worsening comorbidities.
Note: CMS had not released real‑world enrollment numbers as of the demonstration start; agency analyses suggested up to 3.8 million beneficiaries could meet eligibility criteria.
Help us improve.
